MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Executive Promotion
February 28, 2022 07:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Triumph.jpg
Triumph Bancorp to Present at the Raymond James 43rd Institutional Investors Conference on March 7, in Orlando, Florida
February 24, 2022 16:07 ET | Triumph Bancorp, Inc.
DALLAS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Triumph Bancorp, Inc. (Nasdaq: TBK) today announced that Aaron Graft, Vice Chairman and CEO, will present at the Raymond James 43rd Institutional Investors...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
February 03, 2022 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Standard Lithium logo.png
Standard to Present at the Bank of America Securities Virtual Battery and Storage Conference
January 06, 2022 16:29 ET | Standard Lithium
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE: SLI) (FRA: S5L), an innovative technology and lithium...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
November 03, 2021 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
September 16, 2021 02:45 ET | MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
September 16, 2021 02:45 ET | MacroGenics, Inc.
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
September 12, 2021 19:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
September 02, 2021 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
August 05, 2021 16:30 ET | MacroGenics, Inc.
ROCKVILLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...